Skip to main content

Table 2 General and clinical information of the included studies

From: Therapeutic outcome and related predictors of stereotactic body radiotherapy for small liver-confined HCC: a systematic review and meta-analysis of observational studies

Authors

Year

Time of study, design

Country

No. of patients (lesions)

Inclusion of pretreated patients

Sex (M/F)

Median age (range)

CP-A%

ECOG

Viral etiology (HBV + HCV %)

Inclusion of vascular invasion patients

Median/mean longest diameter (range, cm)

Sun et al. [10]

2019

2011–2014, R

China

108 (108)

No

80/28

54 (37–77)

100%

0–1

89.8%

No

2.3 (0.7–4.9)

Parikh et al. [11]

2018

2004–2011, R

USA

32 (NA)

No

20/12

66 (72,71) IQR

NR

NR

NR

No

 ≤ 5.0

Jun et al. [22]

2018

2011–2016, R

Korea

85 (125)

Yes

65/20

Mean 62.6 ± 10

83.5%

NR

68.2%

No

2.23 ± 1.17

Jeong et al. [19]

2018

2012–2013, R

Korea

119 (139)

Yes

97/22

60 (36–90)

90.8%

0–2

87.4%

No

1.7 (≤ 6.0)

Su et al. [23]

2016

2009–2015, R

China

132 (175)

Yes

110/22

58 (30–88)

86.4%

NR

90.2% (HBV only)

No

3.0 (1.1–5.0)

Scorsetti et al. [8]

2015

2010–2014, P

Italy

43 (63)

Yes

31/12

Mean 72 (46–87)

53.5%

0–2

69.8%

Yes

(≤ 6.0)

Kimura et al. [24]

2015

2008–2013, R

Japan

65 (74)

Yes

44–21

73 (49–90)

86.2%

0–1

90.8%

No

1.6 (0.5–5.4)

Shiozawa et al. [12]

2015

2011–2014, R

Japan

35 (35)

No

24/11

Mean 75.1 (55–89)

80.0%

0–2

77.1%

NR

2.86 ± 1.15 (1.2–5.0)

Sanuki et al. [25]

2014

2005–2012, R

Japan

185 (185)

Yes

119/66

74 (40–89)

85.4%

NR

82.2%

Yes

2.4(0.8–5.0)

Yoon et al. [9]

2013

2007–2009, R

Korea

93 (103)

Yes

75/18

61 (42–86)

74.2%

NR

87.1%

No

2.0(≤ 6.0)

Kwon et al. [16]

2010

2004–2007, R

Korea

42 (NA)

Yes

32/10

Mean 60.1 ± 10.9

90.5%

0–1

85.7%

No

(≤ 6.0)a

Jun et al. [17]

2018

2011–2015, R

Korea

117 (136)

Yes

86/31

63 (38–85)

76.1%

NR

65.0%

No

2.1 (1.0–4.0)

Takeda et al. [26]

2016

2007–2012, P

Japan

90 (90)

Yes

58/32

73 (48–85)

91.1%

0–2

88.9%

Yes

2.3 (1.0–4.0)

Jung et al. [18]

2013

2007–2009, R

Korea

92 (NA)

Yes

74/18

61 (42–86)

73.9%

0–2

75.0% (HBV only)

No

(≤ 6.0)

  1. R retrospective, P prospective, NR not reported, IQR interquartile range;
  2. aDiameter is roughly calculated from volume, assuming tumor is spherical